News

Apr 27,2022

OncoC4 Announces Fast Track Designation Granted by the U.S. FDA for ONC-392 Monotherapy in PD(L)1-Resistant NSCLC

Apr 12,2022

Apexigen Announces New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Pembrolizumab in Patients with Metastatic Melanoma Presented at the AACR Annual Meeting 2022

Apr 06,2022

Using AI-Based Image Enhancement to Reduce Brain MRI Scan Times and Improve SNR

Mar 31,2022

DR. YANG LIU ACKNOWLEDGED AS TOP 20 DYNAMIC CEOS OF 2022

Mar 19,2022

Apexigen and Brookline Capital Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Immuno-oncology Company

Mar 17,2022

ONCOC4 RECOGNIZED AS A TOP 10 IMMUNOTHERAPY SOLUTIONS PROVIDERS

Mar 09,2022

C4 Therapeutics Announces FDA Orphan Drug Designation for CFT8634 for the Treatment of Soft Tissue Sarcoma

Feb 28,2022

Twist Bioscience Becomes Digital Preservation Coalition Supporter

No more pages to load

Next page